Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 3
1992 12
1993 22
1994 66
1995 76
1996 94
1997 161
1998 150
1999 229
2000 289
2001 368
2002 395
2003 450
2004 501
2005 623
2006 626
2007 723
2008 791
2009 815
2010 918
2011 1067
2012 1095
2013 1217
2014 1225
2015 1291
2016 1276
2017 1242
2018 1204
2019 1207
2020 1230
2021 1237
2022 1179
2023 1098
2024 467

Text availability

Article attribute

Article type

Publication date

Search Results

20,689 results

Results by year

Filters applied: . Clear all
Page 1
Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Ma Z, Zhang W, Dong B, Xin Z, Ji Y, Su R, Shen K, Pan J, Wang Q, Xue W. Ma Z, et al. Theranostics. 2022 Jun 27;12(11):4965-4979. doi: 10.7150/thno.73152. eCollection 2022. Theranostics. 2022. PMID: 35836810 Free PMC article.
Moreover, we found that docetaxel activated the cGAS/STING pathway in prostate cancer, subsequently induced IFN signaling, resulting in lymphocytes infiltration. In a xenograft mouse model, docetaxel-based chemohormonal therapy prompted the intratumoral infiltration …
Moreover, we found that docetaxel activated the cGAS/STING pathway in prostate cancer, subsequently induced IFN signaling, resulting …
Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization.
Sheng D, Ma W, Zhang R, Zhou L, Deng Q, Tu J, Chen W, Zhang F, Gao N, Dong M, Wang D, Li F, Liu Y, He X, Duan S, Zhang L, Liu T, Liu S. Sheng D, et al. J Immunother Cancer. 2022 May;10(5):e003793. doi: 10.1136/jitc-2021-003793. J Immunother Cancer. 2022. PMID: 35613826 Free PMC article.
BACKGROUND: Although the antitumor efficacy of docetaxel (DTX) has long been attributed to the antimitotic activities, its impact on the tumor microenvironment (TME) has recently gained more attention. ...
BACKGROUND: Although the antitumor efficacy of docetaxel (DTX) has long been attributed to the antimitotic activities, its impact on …
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
Mandel P, Hoeh B, Wenzel M, Preisser F, Tian Z, Tilki D, Steuber T, Karakiewicz PI, Chun FKH. Mandel P, et al. Eur Urol Focus. 2023 Jan;9(1):96-105. doi: 10.1016/j.euf.2022.08.007. Epub 2022 Sep 1. Eur Urol Focus. 2023. PMID: 36058809 Review.
The NMA focusing on the overall cohort of mHSPC demonstrated that triplet therapies (darolutamide, docetaxel, and ADT, and abiraterone, docetaxel, and ADT) were ranked first and second (hazard ratio [HR]: 0.54, 95% confidence interval [CI]: 0.44-0.66; HR: 0.60; 95% …
The NMA focusing on the overall cohort of mHSPC demonstrated that triplet therapies (darolutamide, docetaxel, and ADT, and abirateron …
Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
Menges D, Yebyo HG, Sivec-Muniz S, Haile SR, Barbier MC, Tomonaga Y, Schwenkglenks M, Puhan MA. Menges D, et al. Eur Urol Oncol. 2022 Dec;5(6):605-616. doi: 10.1016/j.euo.2022.04.007. Epub 2022 May 20. Eur Urol Oncol. 2022. PMID: 35599144 Free article. Review.
A benefit-harm assessment showed high probabilities (>60%) for a net clinical benefit with ADT + abiraterone, ADT + enzalutamide, and ADT + apalutamide, while ADT + docetaxel and ADT + docetaxel + darolutamide appeared unlikely (<40%) to be beneficial. ...We f …
A benefit-harm assessment showed high probabilities (>60%) for a net clinical benefit with ADT + abiraterone, ADT + enzalutamide, and ADT …
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Liu Z, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Zheng W, Ma Y, Wang Y, Li S, Yu C, Rivalland G. Zhou C, et al. J Thorac Oncol. 2023 Jan;18(1):93-105. doi: 10.1016/j.jtho.2022.09.217. Epub 2022 Sep 29. J Thorac Oncol. 2023. PMID: 36184068 Free article. Clinical Trial.
INTRODUCTION: The phase 3 RATIONALE-303 trial (NCT03358875) investigated the efficacy and safety of tislelizumab versus docetaxel in pretreated patients with advanced NSCLC. Here, we report the efficacy and safety results and describe the exploratory biomarker analyses. .. …
INTRODUCTION: The phase 3 RATIONALE-303 trial (NCT03358875) investigated the efficacy and safety of tislelizumab versus docetaxel in …
Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT/mTOR pathway in prostate cancer.
Wen H, Qu C, Wang Z, Gao H, Liu W, Wang H, Sun H, Gu J, Yang Z, Wang X. Wen H, et al. FASEB J. 2023 Sep;37(9):e23145. doi: 10.1096/fj.202300980R. FASEB J. 2023. PMID: 37584654
Herein, we examined the role of cuproptosis in the chemotherapeutic resistance of prostate cancer to docetaxel. We treated prostate cancer cell lines with elesclomol-CuCl(2) , as well as with docetaxel. ...In addition, dihydrolipoamide S-acetyltransferase (DLAT) was …
Herein, we examined the role of cuproptosis in the chemotherapeutic resistance of prostate cancer to docetaxel. We treated prostate c …
Docetaxel-Induced Myositis.
Thomas J, Warrier A, Kachare N. Thomas J, et al. J Clin Rheumatol. 2020 Apr;26(3):e62-e63. doi: 10.1097/RHU.0000000000000888. J Clin Rheumatol. 2020. PMID: 30148754 No abstract available.
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu HY, Wu L, Feng J, Zhang Y, Luft AV, Zhou J, Ma Z, Lu Y, Hu C, Shi Y, Baudelet C, Cai J, Chang J. Wu YL, et al. J Thorac Oncol. 2019 May;14(5):867-875. doi: 10.1016/j.jtho.2019.01.006. Epub 2019 Jan 17. J Thorac Oncol. 2019. PMID: 30659987 Free article. Clinical Trial.
Objective response rate was 17% with nivolumab versus 4% with docetaxel; median duration of response was not reached versus 5.3 months. ...In this population with previously treated advanced NSCLC, nivolumab improved OS versus docetaxel. Results were consistent with …
Objective response rate was 17% with nivolumab versus 4% with docetaxel; median duration of response was not reached versus 5.3 month …
Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.
Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E, Schuettfort VM, Kramer G, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF. Mori K, et al. BJU Int. 2022 Apr;129(4):423-433. doi: 10.1111/bju.15507. Epub 2021 Jul 21. BJU Int. 2022. PMID: 34171173 Free PMC article. Review.
Abiraterone (HR 0.85, 95% CrI 0.78-0.93), apalutamide (HR 0.87, 95% CrI 0.77-0.98), and enzalutamide (HR 0.80, 95% CrI 0.73-0.88) were significantly more effective than docetaxel. Regarding AEs, apalutamide was the likely best option among the three ARIs. ...CONCLUSIONS: A …
Abiraterone (HR 0.85, 95% CrI 0.78-0.93), apalutamide (HR 0.87, 95% CrI 0.77-0.98), and enzalutamide (HR 0.80, 95% CrI 0.73-0.88) were signi …
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guerin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
McElree IM, Steinberg RL, Mott SL, O'Donnell MA, Packiam VT. McElree IM, et al. JAMA Netw Open. 2023 Feb 1;6(2):e230849. doi: 10.1001/jamanetworkopen.2023.0849. JAMA Netw Open. 2023. PMID: 36853609 Free PMC article. Clinical Trial.
A total of 312 patients with high-risk treatment-naive NMIBC were included; 174 patients were treated with BCG therapy and 138 were treated with gemcitabine and docetaxel therapy. EXPOSURES: After undergoing complete transurethral resection of bladder tumor, patients recei …
A total of 312 patients with high-risk treatment-naive NMIBC were included; 174 patients were treated with BCG therapy and 138 were treated …
20,689 results
You have reached the last available page of results. Please see the User Guide for more information.